Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1α
2007

How Cancer Cells Respond to EGFR-Targeted Therapy

publication Evidence: moderate

Author Information

Author(s): Lu Yang, Liang Ke, Li Xinqun, Fan Zhen

Primary Institution: The University of Texas M. D. Anderson Cancer Center

Hypothesis

Is hypoxia-inducible factor-1α (HIF-1α) a reliable marker for predicting cancer cell responses to EGFR-targeted therapy?

Conclusion

Downregulation of HIF-1α is associated with positive therapeutic responses of cancer cells to EGFR-targeted therapy.

Supporting Evidence

  • HIF-1α levels decreased in responsive cancer cell lines after treatment.
  • Cells with elevated HIF-1α showed resistance to treatment.
  • HIF-1α downregulation correlated better with treatment response than other markers.

Takeaway

This study found that when cancer cells respond well to certain treatments, a protein called HIF-1α goes down. This might help doctors know if the treatment is working.

Methodology

The study evaluated cancer cell lines with different EGFR statuses and measured changes in HIF-1α levels after treatment with cetuximab and gefitinib.

Limitations

The study primarily focused on cell lines, which may not fully represent patient responses.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1476-4598-6-63

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication